Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025

Rhea-AI Summary

Defence Therapeutics (DTCFF) has announced its participation in the Biotech Showcase™ conference during the J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. The company's CEO and CSO will meet with industry leaders, potential partners, and investors to showcase their proprietary Accum® technology platform, particularly its applications in improving ADCs and developing targeted radiopharmaceutical therapies.

Additionally, Defence has completed the first tranche of its non-brokered private placement, raising $300,000 through units priced at $0.60 each. Each unit includes one common share and one warrant exercisable at $0.75 per share for 24 months. The company paid $24,000 in finder's fees and issued 40,000 finder's warrants. The proceeds will support preclinical and clinical programs and working capital.

Positive

• Secured $300,000 in funding through private placement
• Warrants priced at $0.75, representing 25% premium over unit price

Negative

• Required to pay $24,000 in finder's fees (8% of raised amount)
• Potential dilution from warrant exercise and finder's warrants

Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce its participation to the Biotech Showcase^TM conference next week in San Francisco during the J.P. Morgan Healthcare Conference to meet with industry leaders, partners and potential investors.

The Biotech Showcase is a premier investor conference committed to creating a platform for biotech companies, offering them a unique opportunity to showcase their innovation and engage one-to-one with investors and biopharmaceuticals executives. The life science conference is taking place from January 13-16 in San Francisco during the JP Morgan Healthcare Conference which is the premier healthcare investment symposium attracting thousands of industry leaders and investors.

"Our CSO, Dr. Maxime Parisotto, and I will be actively participating in the healthcare conference and meetings related in San Francisco to meet with global industry leaders, potential partners and investors to reinforce our network in the US ecosystem and more importantly to clearly demonstrate the strength and importance of our proprietary Accum^® technology platform in the US life science market. The Accum^® technology platform has a great potential to play a pivotal role to improve ADCs and in the development of targeted radiopharmaceutical therapies, which we are fully dedicated to expanding in 2025" says Mr. Plouffe, CEO and president of Defence Therapeutics.

The Company is also pleased to announce the closing of the 1^st tranche of its previously announced non-brokered private placement (the "Offering") of units of the Company (the "Units") at a price of $0.60 per Unit for aggregate gross proceeds of $300,000 (the "Closing"). Each Unit consists of one common share in the capital of the Company (each, a "Share") and one common share purchase warrant (each whole, a "Warrant"). Each Warrant is exercisable to acquire one additional Share at an exercise price of $0.75 per Share for a period of 24 months from the date of the Closing (the "Warrant Expiry Date").

In connection with the Closing, the Company paid a cash finder's fee of $24,000 and issued 40,000 finder's warrants (the "Finder's Warrants") to certain qualified arm's length finder. Each Finder's Warrant is exercisable into one Share at an exercise price of $0.75 per Share on or before the Warrant Expiry Date.

The Company intends to use the net proceeds of the Offering to advance its preclinical and clinical programs and for general working capital. All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM^® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236764

FAQ

How much did Defence Therapeutics (DTCFF) raise in its first tranche private placement?

Defence Therapeutics raised $300,000 in the first tranche of its non-brokered private placement at $0.60 per unit.

What are the terms of DTCFF's warrant offering in January 2025?

Each warrant is exercisable at $0.75 per share for a period of 24 months from the closing date.

What is the purpose of Defence Therapeutics' participation in the 2025 Biotech Showcase?

Defence is participating to meet with industry leaders, potential partners, and investors to showcase their Accum® technology platform and expand their US market presence.

How will Defence Therapeutics (DTCFF) use the proceeds from its January 2025 private placement?

The company will use the net proceeds to advance its preclinical and clinical programs and for general working capital purposes.